摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3-(4-(benzyloxy)phenyl)-1-(oxazolo[4,5-b]pyridin-2-yl)propan-1-ol | 945414-35-7

中文名称
——
中文别名
——
英文名称
3-(4-(benzyloxy)phenyl)-1-(oxazolo[4,5-b]pyridin-2-yl)propan-1-ol
英文别名
1-([1,3]oxazolo[4,5-b]pyridin-2-yl)-3-(4-phenylmethoxyphenyl)propan-1-ol
3-(4-(benzyloxy)phenyl)-1-(oxazolo[4,5-b]pyridin-2-yl)propan-1-ol化学式
CAS
945414-35-7
化学式
C22H20N2O3
mdl
——
分子量
360.412
InChiKey
QZBFXCBSLIVYRP-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4
  • 重原子数:
    27
  • 可旋转键数:
    7
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.18
  • 拓扑面积:
    68.4
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    3-(4-(benzyloxy)phenyl)-1-(oxazolo[4,5-b]pyridin-2-yl)propan-1-ol戴斯-马丁氧化剂 作用下, 以 二氯甲烷 为溶剂, 以50%的产率得到3-(4-(benzyloxy)phenyl)-1-(oxazolo[4,5-b]pyridin-2-yl)propan-1-one
    参考文献:
    名称:
    Structure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase
    摘要:
    A systematic study of the structure-activity relationships of 2b (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the C2 acyl side chain. A series of aryl replacements or substituents for the terminal phenyl group provided effective inhibitors (e.g., 5c, aryl = 1- napthyl, K-i = 2.6 nM), with 5hh (aryl = 3-ClPh, K-i = 900 pM) being 5-fold more potent than 2b. Conformationally restricted C2 side chains were examined, and many provided exceptionally potent inhibitors, of which 11j (ethylbiphenyl side chain) was established to be a 750 pM inhibitor. A systematic series of heteroatoms (O, NMe, S), electron-withdrawing groups (SO, SO2), and amides positioned within and hydroxyl substitutions on the linking side chain were investigated, which typically led to a loss in potency. The most tolerant positions provided effective inhibitors (12p, 6-position S, K-i = 3 nM, or 13d, 2-position OH, K-i = 8 nM) comparable in potency to 2b. Proteome-wide screening of selected inhibitors from the systematic series of > 100 candidates prepared revealed that they are selective for FAAH over all other mammalian serine proteases.
    DOI:
    10.1021/jm061414r
  • 作为产物:
    参考文献:
    名称:
    WO2008/147553
    摘要:
    公开号:
点击查看最新优质反应信息

文献信息

  • TETRACYCLIC INHIBITORS OF FATTY ACID AMIDE HYDROLASE
    申请人:Boger Dale L.
    公开号:US20100249078A1
    公开(公告)日:2010-09-30
    Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
    本文描述了某些四环化合物,可用于制备药物组合物和方法,用于治疗由脂肪酸酰胺解酶(FAAH)活性介导的疾病状态、障碍和病况。因此,这些化合物可以用于治疗焦虑、疼痛、炎症、睡眠障碍、进食障碍或运动障碍(例如多发性硬化)。
  • Tetracyclic inhibitors of fatty acid amide hydrolase
    申请人:Boger Dale L.
    公开号:US08372823B2
    公开(公告)日:2013-02-12
    Certain tetracyclic compounds are described, which may be used in pharmaceutical compositions and methods for treating disease states, disorders, and conditions mediated by fatty acid amide hydrolase (FAAH) activity. Thus, the compounds may be administered to treat, e.g., anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders (such as multiple sclerosis).
    本文描述了某些四环类化合物,可用于制备药物组合物和治疗由脂肪酸酰胺酶(FAAH)活性介导的疾病状态、疾病和病症的方法。因此,该化合物可用于治疗焦虑、疼痛、炎症、睡眠障碍、饮食障碍或运动障碍(如多发性硬化)等疾病。
  • US8372823B2
    申请人:——
    公开号:US8372823B2
    公开(公告)日:2013-02-12
查看更多

同类化合物

甲基吡噁磷 甲基吡啶磷-d6 恶唑并[5,4-B]吡啶-2-胺二盐酸盐 恶唑并[5,4-B]吡啶-2-胺 恶唑并[5,4-B]吡啶-2(1H)-硫酮 恶唑并[4,5-B]吡啶-2(3H)硫酮 噁唑并[5,4-c]吡啶-2-胺 噁唑并[5,4-c]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶-2(1h)-酮 噁唑并[5,4-b]吡啶 噁唑并[4,5-c]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-胺 噁唑并[4,5-b]吡啶-2-羧酸乙酯 噁唑并[4,5-b]吡啶-2(3H)-酮,6-溴-3-(苯基甲基)- 噁唑并[4,5-b]吡啶-2(3H)-酮,6-乙酰基-3-[2-(2-吡啶基)乙基]- 噁唑并[4,5-b]吡啶-2(3H)-酮,3-(2-羰基丙基)- 噁唑并[4,5-b]吡啶-2(3H)-酮,3-(2-氨基乙基)-,盐酸盐 噁唑并[4,5-b]吡啶,2-(1-甲基乙基)-(9CI) 噁唑并[4,5-b]吡啶 噁唑并[4,5-C]吡啶-2(3H)-硫酮 噁唑并[4,5-C]吡啶 乙酮,1-噁唑并[4,5-b]吡啶-2-基-(9CI) [1,3]恶唑并[4,5-c]吡啶-6-羧酸 7-溴恶唑并[4,5-C]吡啶 7-溴-2-甲基-F唑并[4,5-C]吡啶 7-溴-2-乙基恶唑并[4,5-C]吡啶 6-溴恶唑并[5,4-B]吡啶-2-胺 6-溴恶唑并[5,4-B]吡啶 6-溴噁唑并[4,5-b]吡啶 6-溴-3H-恶唑并[4,5-b]吡啶-2-酮 6-溴-2-甲基噁唑并[5,4-b]吡啶 6-溴-2-甲基噁唑并[4,5-B]吡啶 6-溴-2-(三氟甲基)噁唑并[5,4-B]吡啶 6-溴-2-(三氟甲基)噁唑并[4,5-b]吡啶 6-氯恶唑并[4,5-b]吡啶-2(3H)-酮 5-甲基噁唑并[4,5-b]吡啶-2(3h)-酮 5-甲基[1,3]恶唑并[5,4-b]吡啶-2-醇 5-甲基-3H-恶唑并[4,5-B]吡啶-2-硫酮 5-溴[4,5-B]吡啶 5-溴-3H-恶唑并[4,5-b]吡啶-2-酮 3-[2-(4-氯苯基)乙基]-2-苯基亚氨基-1,3-噻唑烷-4-酮 3-(2-溴乙基)恶唑并[4,5-b]吡啶-2(3H)-酮 3-(2-吗啉-4-基乙基)[1,3]噁唑并[4,5-b]吡啶-2(3H)-酮 2-甲硫基唑并[4,5-B]吡啶 2-甲基硫基 [ 1,3 ] 恶唑酮[5,4-C]吡啶 2-甲基噁唑并[5,4-c]吡啶 2-甲基噁唑并[5,4-b]吡啶 2-甲基吡啶并噁唑 2-甲基[1,3]恶唑并[4,5-c]吡啶-7-胺 2-甲基[1,3]噁唑并[4,5-b]吡啶